<DOC>
	<DOCNO>NCT01514487</DOCNO>
	<brief_summary>This trial conduct Oceania . The aim trial test bioequivalence two new liraglutide formulation pH 7.9 8.15 plan Phase 3 formulation pH 7.7 .</brief_summary>
	<brief_title>Comparison Three Liraglutide Formulations Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Healthy subject Good general health judge investigator , base medical history , physical examination include 12lead ECG ( electrocardiogram ) , vital sign blood urinary laboratory assessment . Body Mass Index ( BMI ) 1827 kg/m^2 , inclusive History clinically significant renal , hepatic , cardiovascular , pulmonary , gastrointestinal , metabolic , endocrine , haematological , neurological , psychiatric disease major disorder may interfere objective study , judge investigator Family personal history Primary hyperparathyroidism pheochromocytoma thyroid malignancy multiple endocrine neoplasia Impaired renal function Uncontrolled treated/untreated hypertension Any clinically significant abnormal ECG Active hepatitis B and/or active hepatitis C Positive HIV ( human immunideficiency virus ) antibodies Known suspect allergy trial product ( ) relate product Pregnant , breastfeed intention become pregnant use adequate contraceptive measure Prescription nonprescription medication , except paracetamol vitamin History alcoholism drug abuse last 12 month Smoking 10 cigarette per day , equivalent tobacco product Habitual excessive consumption methylxanthinecontaining beverage food ( coffee , tea , soft drink cola , chocolate ) judge Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>